gen iii microarray spotter  (Amersham Pharmacia Biotech Ltd)

Journal: The Journal of Lipid Research

Article Title: Prediction of PPAR- ligand-mediated physiological changes using gene expression profiles

doi: 10.1194/jlr.d300239-jlr200

Figure Lengend Snippet: Fig. 4. Relationship between regulated target genes and the relative drug peroxisome proliferator-acti- vated receptor- (PPAR-) efficacy. A: Comparison of quantitative expression levels as measured in microar- rays and Northern blot analysis and the relative PPAR- efficacies of the tested compounds using linear regres- sion analysis. Fold regulations as calculated in Table 2 were used for the microarray data, whereas signal in- tensities for the genes in Northern blots were col- lected using a PhosphorImager and normalized to the signals for ribosomal phosphoprotein 36B4. For apoli- poprotein C-III (apoC-III), the log fold change was used because this gene is downregulated and its ex- pression ratios lie between 1 and 0. B: Northern blots showing the expression of peroxisomal enoyl-CoA:hy- drotase-3-hydroxyacyl-CoA bifunctional enzyme (bi- functional enzyme), apoC-III, and ribosomal phos- phoprotein 36B4.

Article Snippet: The purified PCR products were mixed 1:1 in DMSO (Sigma, St. Louis, MO) and rearranged in 384-well plates. cDNA targets were spotted in duplicate onto silanized glass slides (Amersham Biosciences, Buckinghamshire, UK) at 55% relative humidity using the Molecular Dynamics Gen. III microarray spotter.

Techniques: Comparison, Expressing, Northern Blot, Microarray, Functional Assay